ทฌวัษ็ว๘app

Oncology/Hematology

Myeloma

More in Myeloma

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

Joseph Mikhael, MD, leads a roundtable discussion on two positive phase III trials from ASCO

Jun 14, 2024
image
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma

Second belantamab mafodotin-containing triplet to show potency in this setting

Jun 02, 2024
ASCO over a photo of McCormick Place in Chicago, IL
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise

News, features, and commentary about cancer-related issues

May 10, 2024
Onco Break over a computer rendering of a cancer cell.
Opinion
Ending Oncology's Toxic Relationship With High Chemotherapy Doses

Optimizing doses can improve patient outcomes and lower costs

May 10, 2024
A close up photo of a womanโ€™s hand with an IV line attached.
Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCT

ORR reaches 90% with isatuximab plus KRd in newly diagnosed disease

Apr 26, 2024
An image of isatuximab tablets.
FDA Approves Earlier Use of CAR-T Products for Myeloma

Carvykti and Abecma move to second- and third-line, respectively

Apr 08, 2024
FDA APPROVED ciltacabtagene autoleucel (Carvykti), idecabtagene vicleucel (Abecma) over 3D multiple myeloma cells.
High Response Rate in R/R Multiple Myeloma With Bispecific Antibody

ORR of 71% that deepened over time and favorable safety profile with linvoseltamab

Apr 08, 2024
ACC over a photo of Georgia World Congress Center in Atlanta, GA
Chemo and Heart Disease; Flawed Lung Cancer Screening; New Vax Recommendations

News, features, and commentary about cancer-related issues

Mar 29, 2024
Onco Break over a computer rendering of a cancer cell.
FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myeloma

Cilta-cel, ide-cel win support despite concerns about early mortality risk

Mar 16, 2024
FDA ODAC ciltacabtagene autoleucel (cilta-cel, Carvykti) and idecabtagene vicleucel (ide-cel, Abecma) over multiple myeloma.
Early Death Risk Muddies Risk-Benefit Assessment of CAR-T Therapies for Myeloma

FDA advisory panel to weigh the evidence for cilta-cel, ide-cel in day-long meeting

Mar 14, 2024
 FDA ODAC ciltacabtagene autoleucel (cilta-cel, Carvykti) and idecabtagene vicleucel (ide-cel, Abecma) over multiple myeloma.
A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu

News, features, and commentary about cancer-related issues

Mar 07, 2024
Onco Break over a computer rendering of a cancer cell.
Toxic Gas That Sterilizes Medical Devices Prompts Safety Rule Update

The EPA is set to take action after public outcry

Mar 03, 2024
A photo of families holding handwritten signs at a protest outside a sterilization plant in Illinois.
More in Myeloma